REGENERON PHARMACEUTICALS, INC.

Lobbying client · New York · filed 2025 to 2026

Biopharmaceutical development and manufacturing

$300,000 Reported spend

6 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (196249), not by name.

Firms hired 1

CRANE STRATEGIES $300,000 6 filings

Reported by year 2 years

2026 $100,000 2 filings
2025 $200,000 4 filings

Issues lobbied 1

Budget/Appropriations 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 3

Health & Human Services, Dept of (HHS) 6
HOUSE OF REPRESENTATIVES 6
SENATE 6

Recent filings 6 total

Q2

CRANE STRATEGIES

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $50,000 income · posted Aug 3, 2026

View → Q1

CRANE STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $50,000 income · posted May 4, 2026

View → Q4

CRANE STRATEGIES

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $50,000 income · posted Jan 21, 2026

View → Q3

CRANE STRATEGIES

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $50,000 income · posted Oct 1, 2025

View → Q2

CRANE STRATEGIES

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $50,000 income · posted Jul 1, 2025

View → Q1

CRANE STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $50,000 income · posted May 5, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.